EUCTR2006-006373-25-AT
Active, not recruiting
Not Applicable
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP-690,550 - N/A
Pfizer Ltd, Ramsgate Road, Sandwich CT139NJ, UK0 sites300 target enrollmentFebruary 12, 2007
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- CP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).
- Sponsor
- Pfizer Ltd, Ramsgate Road, Sandwich CT139NJ, UK
- Enrollment
- 300
- Status
- Active, not recruiting
- Last Updated
- 13 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Evidence of a signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial.
- •Subject has received at least one dose of study drug and has discontinued participation in any Phase 2B or 3 randomized, controlled, or open label (qualifying study) of CP 690,550 for the treatment of RA.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Any subject who refuses to provide consent.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF cp 690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-006373-25-SEPfizer Ltd, Ramsgate Road, Sandwich CT139NJ, UK300
Active, not recruiting
Not Applicable
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF cp 690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-006373-25-CZPfizer Inc. 235 East 42nd Street, New York, NY10017300
Active, not recruiting
Not Applicable
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF cp 690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-006373-25-BGPfizer Inc. 235 East 42nd Street, New York, NY10017300
Active, not recruiting
Not Applicable
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP-690,550 - N/AEUCTR2006-006373-25-FIPfizer Inc. 235 East 42nd Street, New York, NY10017300
Active, not recruiting
Phase 1
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP-690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritisEUCTR2006-006373-25-GBPfizer Inc. 235 East 42nd Street, New York, NY10017300